PRKN and Parkinson disease: These molecules work exclusively with the interaction of two pUb molecules, bypassing the need for PINK1 phosphorylation of parkin and providing a potential rescue pathway for genetic PD-based substitutions in the Ubl domain that limit its folding, phosphorylation, and binding.